Neuropathic Back Pain Epidemiology Forecast 2025-2034

Neuropathic back pain is caused by nerve dysfunction or damage and originates from a compressed nerve in the spine. The prevalence of neuropathic low back pain is estimated to be around 5% and is linked with reduced quality of life, increased likelihood and severity of comorbidities, and higher healthcare costs.

Neuropathic Back Pain Epidemiology Forecast Report Coverage

The “Neuropathic Back Pain Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of neuropathic back pain. It projects the future incidence and prevalence rates of Neuropathic Back pain across various populations. The study covers age and type as major determinants of the neuropathic back pain-affected population. The report highlights patterns in the prevalence of neuropathic back pain over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of neuropathic back pain in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Neuropathic Back Pain: Disease Overview

Neuropathic back pain is defined as a non-physiological pain that occurs when the nervous system suffers damage. This malfunctioning of the nervous system can lead to pain in the lower limbs and the spine. Neuropathic back pain can be caused by certain diseases, a herniated disc, or an injury. It can occur in response to a stimulus or spontaneously. The risk of neuropathic back pain increases in patients with diabetes, HIV/AIDS, shingles, and alcohol use disorder. People with physically demanding jobs often suffer from back pain and nerve damage.

Neuropathic Back Pain: Treatment Overview

Neuropathic back pain is typically treated with a combination of medications, physical therapy, and other treatment options. Over-the-counter pain relievers such as ibuprofen and acetaminophen are widely used by the affected patients. Antidepressants can aid in relieving pain along with addressing symptoms of anxiety and depression. Other treatment alternatives include topical treatments and antiseizure medications. Physical therapy is also recommended for stiffness, soreness, and discomfort.

Epidemiology

The neuropathic back pain epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for neuropathic back pain by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for neuropathic back pain and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The prevalence of neuropathic low back pain is estimated to be about 5%. However, some reports indicate that 16 to 55% of chronic low back pain patients have possible neuropathic pain components.
• According to a prospective cohort study published in the Clinical Journal of Pain (2020), the prevalence of neuropathic pain varies from 48% to 74%.
• Studies show that the incidence of neuropathic pain ranges from 0.82% to about 3% in the general population. Further, the overall incidence among chronic pain patients is reported to be 6.9%.
• Approximately 3 out of 10 patients aged over 70 years are affected by neuropathic pain.

Country-wise Neuropathic Back Pain Epidemiology

The neuropathic back pain epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of neuropathic back pain varies significantly between countries due to differences in lifestyle patterns, occupational hazards, prevalence of conditions like diabetes or spinal injuries, and genetic predispositions, among others. As per a cross-sectional analysis conducted in a large United Kingdom cohort (2023), 76,095 participants (51.1%) were affected by chronic pain, with the overall prevalence of neuropathic pain estimated to be 9.2%.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of neuropathic back pain based on several factors.
• Neuropathic Back Pain Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of neuropathic back pain are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of neuropathic back pain epidemiology in the 8 major markets?
• What will be the total number of patients with neuropathic back pain across the 8 major markets during the forecast period?
• What was the country-wise prevalence of neuropathic back pain in the 8 major markets in the historical period?
• Which country will have the highest number of neuropathic back pain patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of neuropathic back pain during the forecast period of 2025-2034?
• What are the currently available treatments for neuropathic back pain?
• What are the disease risks, signs, symptoms, and unmet needs of neuropathic back pain?

This product will be delivered within 3-5 business days.